Trial
NCT00881621
Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Georgetown University
Collaborators
GlaxoSmithKline
Condition
Pancreas Cancer
Intervention
Lapatinib and Capecitabine
Why stopped
slow enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-03